Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4044778 | 0.83 | MEN1 (0.47) | ALDH1A1 | |
| SCHEMBL615516 | 0.81 | TSHR (0.65) | TSHRLTA4HSMN1; SMN2CARM1PRMT6 | |
| SCHEMBL12474 | 0.79 | PYCR1 (0.50) | TSHRLTA4HSMN1; SMN2CARM1PRMT6 | |
| SCHEMBL29109904 | 0.79 | LTA4H (0.45) | TSHRLTA4HSMN1; SMN2CARM1PRMT6 | |
| SCHEMBL18227681 | 0.79 | MEN1 (0.47) | TSHRLTA4HCARM1PRMT6PRMT8 | |
| SCHEMBL3151763 | 0.78 | LTA4H (0.47) | TSHRLTA4HSMN1; SMN2CARM1PRMT6 | |
| SCHEMBL16549287 | 0.78 | MEN1 (0.52) | TSHRLTA4HSMN1; SMN2PYCR1SIGMAR1 | |
| SCHEMBL1239426 | 0.78 | KDM4E (0.59) | TSHRLTA4HSMN1; SMN2MAOBBRAF | |
| SCHEMBL3038304 | 0.77 | CARM1 (0.41) | SMN1; SMN2CARM1PRMT6PRMT8MAOB | |
| SCHEMBL26012094 | 0.75 | LTA4H (0.45) | TSHRLTA4HSMN1; SMN2CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113149885-A | EBNA1 inhibitors and methods of using the same | 威斯塔解剖学和生物学研究所 | 2021-07-23 | — | — | CN | claimed |
| US-20180305312-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-25 | — | — | US | claimed |
| US-11912659-B2 | EBNA1 inhibitors and methods using same | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2024-02-27 | — | — | US | disclosed |
| CN-113149885-A | EBNA1 inhibitors and methods of using the same | 威斯塔解剖学和生物学研究所 | 2021-07-23 | — | — | CN | disclosed |
| EP-3294705-B1 | EBNA1 INHIBITORS AND METHODS USING SAME | WISTAR INST (US) | 2021-07-21 | — | — | EP | disclosed |
| US-10981867-B2 | EBNA1 inhibitors and methods using same | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2021-04-20 | — | — | US | disclosed |
| CN-107848964-B | EBNA1 inhibitors and methods of using the same | 威斯塔解剖学和生物学研究所 | 2021-03-19 | — | — | CN | disclosed |
| US-10442763-B2 | EBNA1 inhibitors and methods using same | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180305312-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-25 | — | — | US | disclosed |
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305312-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | MLLT1, EBNA1BP2, MALT1 | TSHR 4040/4885LTA4H 1183/4885SMN1; SMN2 2354/4885 |
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | TSHR 2601/4885LTA4H 4543/4885SMN1; SMN2 4397/4885 |
| US-10981867-B2 | EBNA1 inhibitors and methods using same | MLLT1, EBNA1BP2, MALT1 | TSHR 4040/4885LTA4H 1183/4885SMN1; SMN2 2354/4885 |
| US-11912659-B2 | EBNA1 inhibitors and methods using same | MLLT1, EBNA1BP2, MALT1 | TSHR 4040/4885LTA4H 1183/4885SMN1; SMN2 2354/4885 |
| US-10442763-B2 | EBNA1 inhibitors and methods using same | MLLT1, EBNA1BP2, MALT1 | TSHR 4040/4885LTA4H 1183/4885SMN1; SMN2 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.